Warning Letters Special Report: Top Problem Areas Were Investigations, Testing And Sterility

Drug GMP warning letters last year cited testing inadequacies and poor batch failure and complaint investigations more than any other problem, this third part of our in-depth series reports, followed by sterility assurance issues that were somewhat driven by concerns about water systems. Most were US-focused – a pandemic limitation but also a reminder that drug GMP problems are not limited to China and India.

2022 Warning Letters Special Report
the top problem areas • Source: Shutterstock

More from Manufacturing

More from Compliance